Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun 15;205(12):1806-10.
doi: 10.1093/infdis/jis285. Epub 2012 Apr 5.

Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials

Kathryn E Stephenson  1 , John Hural, Susan P Buchbinder, Faruk Sinangil, Dan H Barouch
Affiliations

Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials

Kathryn E Stephenson et al. J Infect Dis. .

Abstract

The Step study of a recombinant adenovirus serotype 5 (Ad5)-based human immunodeficiency virus type 1 (HIV-1) vaccine revealed an increased risk of HIV-1 acquisition in vaccinees who were Ad5 seropositive at baseline. We therefore investigated whether preexisting Ad seropositivity to 7 different Ad serotypes was associated with increased risk of HIV-1 infection in 3 HIV-1 vaccine efficacy trials. In a case-control study involving 1570 adults enrolled in the VAX003 and VAX004 trials of a recombinant protein subunit HIV-1 vaccine and in the Step study, we observed that preexisting seropositivity to multiple Ad serotypes was not intrinsically associated with increased risk of HIV-1 acquisition.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Percent of subjects with preexisting adenovirus seropositivity by HIV-1 status and subgroup. P, 2-sided Fischer exact test; OR, odds ratio. A, Subjects are divided by vaccine/placebo status and individual vaccine trial. For the VAX004 study, Ad48 data are missing for 1 HIV-1–infected, vaccinated subject. For the Step study, Ad35 data are missing for 3 HIV-1-uninfected, unvaccinated subjects, and 1 HIV-1–infected, vaccinated subject. *Ad5 data not analyzed in the Step study as this variable was included in selecting control subjects. B, Subjects are divided by vaccine/placebo and circumcision status in the Step study. Among circumcised subjects, Ad35 data are missing for 3 HIV-1-uninfected placebo recipients and 1 HIV-1–uninfected vaccinated subject.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Barouch DH. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS. 2010;5:386–90. - PMC - PubMed
    1. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881–93. - PMC - PubMed
    1. Curlin ME, Cassis-Ghavami F, Magaret AS, et al. Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study. AIDS. 2011;25:153–8. - PMC - PubMed
    1. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;194:1661–71. - PubMed
    1. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191:654–65. - PubMed

Publication types

Substances